Clinical diagnosis and treatment of 37 cases of gallbladder neuroendocrine carcinoma.
Clinical features
Gallbladder neuroendocrine carcinoma
Surgical treatment
Survival time
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
23
02
2024
accepted:
01
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
This study aims to investigate the clinical and pathological characteristics, treatment approaches, and prognosis of gallbladder neuroendocrine carcinoma (GB-NEC). Retrospective analysis was conducted on the clinical data of 37 patients with GB-NEC admitted to Shanxi Cancer Hospital from January 2010 to June 2023. The study included an examination of their general information, treatment regimens, and overall prognosis. Twelve cases, either due to distant metastasis or other reasons, did not undergo surgical treatment and received palliative chemotherapy (Group 1). Two cases underwent simple cholecystectomy (Group 2); four patients underwent palliative tumor resection surgery (Group 3), and nineteen patients underwent radical resection surgery (Group 4). Among the 37 GB-NEC patients, the average pre-surgery CA19-9 level was 113.29 ± 138.45 U/mL, and the median overall survival time was 19 months (range 7.89-30.11 months). Of these, 28 cases (75.7%) received systemic treatment, 25 cases (67.6%) underwent surgical intervention, and 16 cases (64.0%) received postoperative adjuvant treatment, including combined radiochemotherapy or chemotherapy alone. The median overall survival time was 4 months (0.61-7.40 months) for Group 1 (n = 12), 8 months for Group 2 (n = 2), 21 months (14.67-43.33 months) for Group 3 (n = 4), and 19 months (range 7.89-30.11 months) for Group 4 (n = 19). A significant difference in median overall survival time was observed between Group 1 and Group 4 (P = 0.004). Surgery remains the primary treatment for GB-NEC, with radical resection potentially offering greater benefits to patient survival compared to other therapeutic options. Postoperative adjuvant therapy has the potential to extend patient survival, although the overall prognosis remains challenging.
Identifiants
pubmed: 38877554
doi: 10.1186/s12957-024-03436-z
pii: 10.1186/s12957-024-03436-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Informations de copyright
© 2024. The Author(s).
Références
Hickman L, Contreras C. Gallbladder Cancer: diagnosis, Surgical Management, and adjuvant therapies. Surg Clin North Am. 2019;99(2):337–55.
pubmed: 30846038
doi: 10.1016/j.suc.2018.12.008
Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855–63.
pubmed: 25918282
doi: 10.1200/JCO.2014.60.2532
Lee SM, Sung CO. Neuroendocrine carcinomas of the gallbladder: a clinicopathologic and immunohistochemical analysis of 34 resected cases. Am J Surg Pathol. 2020;44(10):1308–21.
pubmed: 32739935
doi: 10.1097/PAS.0000000000001536
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
pubmed: 28448665
pmcid: 5824320
doi: 10.1001/jamaoncol.2017.0589
Ayub F, Saif MW. Neuroendocrine tumor of the cystic Duct: a rare and incidental diagnosis. Cureus. 2017;9(10):e1755.
pubmed: 29226045
pmcid: 5718876
Eltawil KM, Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44(10):687–95.
pubmed: 20375728
doi: 10.1097/MCG.0b013e3181d7a6d4
Kamboj M, Gandhi JS, Gupta G, Sharma A, Pasricha S, Mehta A, Chandragouda D, Sinha R. Neuroendocrine carcinoma of Gall bladder: a Series of 19 cases with review of literature. J Gastrointest Cancer. 2015;46(4):356–64.
pubmed: 26208508
doi: 10.1007/s12029-015-9745-9
Yan S, Wang Y, Chen X, Zhang Y, Huang Z, Zhao J, Zhou J, Li Z, Bi X, Luo Z, et al. Clinical analysis of 15 cases of Gallbladder Neuroendocrine Carcinoma and comparison with Gallbladder Adenocarcinoma using a propensity score matching. Cancer Manag Res. 2020;12:1437–46.
pubmed: 32161496
pmcid: 7049775
doi: 10.2147/CMAR.S227501
Chu H, Zhang C, Shi Y, Wu W, Hu Z, Zhang J, Huang D. Gallbladder neuroendocrine carcinoma: a single center experience. Med (Baltim). 2020;99(36):e21912.
doi: 10.1097/MD.0000000000021912
Cen D, Liu H, Wan Z, Lin Z, Wang Y, Xu J, Liang Y. Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect. 2019;8(9):1273–81.
pubmed: 31398710
pmcid: 6733363
doi: 10.1530/EC-19-0124
Niu C, Wang S, Guan Q, Ren X, Ji B, Liu Y. Neuroendocrine tumors of the gallbladder. Oncol Lett. 2020;19(5):3381–8.
pubmed: 32269610
pmcid: 7115111
Monier A, Saloum N, Szmigielski W, Alrashid A, Napaki SME. Neuroendocrine tumor of the gallbladder. Pol J Radiol. 2015;80:228–31.
pubmed: 26000067
pmcid: 4424909
doi: 10.12659/PJR.893705
Yun SP, Shin N, Seo HI. Clinical outcomes of small cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. World J Gastroenterol. 2015;21(1):269–75.
pubmed: 25574101
pmcid: 4284345
doi: 10.3748/wjg.v21.i1.269
Chen C, Wang L, Liu X, Zhang G, Zhao Y, Geng Z. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8(7):8218–26.
pubmed: 26339390
pmcid: 4555718
Kim J, Lee WJ, Lee SH, Lee KB, Ryu JK, Kim Y-T, Kim S-W, Yoon YB, Hwang JH, Han H-S, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. Dig Liver Dis. 2011;43(12):965–70.
pubmed: 21856258
doi: 10.1016/j.dld.2011.07.010
Ayabe RI, Wach M, Ruff S, Martin S, Diggs L, Wiemken T, Hinyard L, Davis JL, Luu C, Hernandez JM. Primary gallbladder neuroendocrine tumors: insights into a Rare Histology using a large National Database. Ann Surg Oncol. 2019;26(11):3577–85.
pubmed: 31102094
pmcid: 8189165
doi: 10.1245/s10434-019-07440-6
Lee KJ, Cho JH, Lee SH, Lee KH, Park BK, Lee JK, Woo SM, Ryu JK, Lee JK, Kim YS, et al. Clinicopathological characteristics of biliary neuroendocrine neoplasms: a multicenter study. Scand J Gastroenterol. 2017;52(4):437–41.
pubmed: 27924650
doi: 10.1080/00365521.2016.1261938
Zhou S, Jiang S, Chen W, Yin H, Dong L, Zhao H, Han S, He X. Biliary neuroendocrine neoplasms: analysis of prognostic factors and development and validation of a Nomogram. Front Oncol. 2021;11:654439.
pubmed: 34350109
pmcid: 8327779
doi: 10.3389/fonc.2021.654439
Wang P, Chen J, Jiang Y, Jia C, Pang J, Wang S, Chang X. Neuroendocrine neoplasms of the gallbladder: a clinicopathological analysis of 13 patients and a review of the literature. Gastroenterol Res Pract. 2021;2021:5592525.
pubmed: 34122537
pmcid: 8166508
doi: 10.1155/2021/5592525
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.
pubmed: 31433515
doi: 10.1111/his.13975
Liu W, Chen W, Chen J, Hong T, Li B, Qu Q, He X. Neuroendocrine carcinoma of gallbladder: a case series and literature review. Eur J Med Res. 2019;24(1):8.
pubmed: 30717775
pmcid: 6362567
doi: 10.1186/s40001-019-0363-z
Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D’Angelica M, Dematteo RP, Blumgart LH, O’Reilly EM. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98(7):485–9.
pubmed: 18802958
doi: 10.1002/jso.21141
Shintaku M, Kataoka K, Kawabata K. Mixed adenoneuroendocrine carcinoma of the gallbladder with squamous cell carcinomatous and osteosarcomatous differentiation: report of a case. Pathol Int. 2013;63(2):113–9.
pubmed: 23464969
doi: 10.1111/pin.12029
Ren X, Jiang H, Sun K, Qin X, Qu Y, Xia T, Chen Y. Mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder: case report and literature review. Diagn Pathol. 2022;17(1):51.
pubmed: 35715834
pmcid: 9206291
doi: 10.1186/s13000-022-01231-6
Siddamreddy S, Meegada S, Syed A, Sarwar M, Muppidi V. Gallbladder neuroendocrine carcinoma: a rare endocrine tumor. Cureus. 2020;12(3):e7487.
pubmed: 32368420
pmcid: 7192559
Raiker R, Chauhan A, Hasanein H, Burkeen G, Horn M, Veedu J, Vela C, Arnold S, Kolesar J, Anthony L, et al. Biliary tract large cell neuroendocrine carcinoma: current evidence. Orphanet J Rare Dis. 2019;14(1):266.
pubmed: 31752927
pmcid: 6869278
doi: 10.1186/s13023-019-1230-2
Garcia-Carbonero R, Jimenez-Fonseca P, Teulé A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014;16(12):1025–34.
pubmed: 25183048
pmcid: 4239790
doi: 10.1007/s12094-014-1214-6
Lee J-M, Hwang S, Lee S-G, Lee Y-J, Park K-M, Kim K-H, Ahn C-S, Kim M-H, Lee S-K, Kim MW. Neuroendocrine tumors of the gallbladder: twelve cases in a single institution. Hepatogastroenterology. 2010;57(102–103):1064–8.
pubmed: 21410032
Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72(1):39–45.
pubmed: 31997233
doi: 10.1007/s13304-020-00710-z
Sharma A, Saluja SS, Nag HH, Sharma M, Sakhuja P. Neuroendocrine carcinoma of the Gallbladder. Am Surg. 2022;88(11):2768–70.
pubmed: 32935998
doi: 10.1177/0003134820951466
Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28(1):26–54.
pubmed: 33259690
doi: 10.1002/jhbp.870
Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. Abdom Radiol (NY). 2021;46(6):2474–89.
pubmed: 33386907
doi: 10.1007/s00261-020-02871-2
Zheng Z, Chen C, Li B, Liu H, Zhou L, Zhang H, Zheng C, He X, Liu W, Hong T, et al. Biliary neuroendocrine neoplasms: clinical profiles, management, and analysis of prognostic factors. Front Oncol. 2019;9:38.
pubmed: 30805307
pmcid: 6370735
doi: 10.3389/fonc.2019.00038
Liu W, Chen W, He X, Qu Q, Hong T, Li B. Cholecystectomy with gallbladder bed cautery might be sufficient for T1bN0M0 neuroendocrine carcinoma of gallbladders: cases report and literature review. Med (Baltim). 2017;96(47):e8778.
doi: 10.1097/MD.0000000000008778
Li P, Song L. Prognostic Evaluation for Patients over 45 Years Old with Gallbladder Adenocarcinoma Resection: A SEER-Based Nomogram Analysis. Biomed Res Int 2020, 2020:6370946.
You YH, Choi DW, Heo JS, Han IW, Choi SH, Jang K-T, Han S. Can surgical treatment be justified for neuroendocrine carcinoma of the gallbladder? Med (Baltim). 2019;98(11):e14886.
doi: 10.1097/MD.0000000000014886
Gogna S, Samson D, Gachabayov M, Rojas A, Felsenreich DM, Koo D, Gu K, Quintero L, Miller KR, Azim A, et al. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch Surg. 2022;407(1):197–206.
pubmed: 34236488
doi: 10.1007/s00423-021-02256-z
Sahara K, Tsilimigras DI, Maithel SK, Abbott DE, Poultsides GA, Hatzaras I, Fields RC, Weiss M, Scoggins C, Isom CA, et al. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121(3):503–10.
pubmed: 31907941
pmcid: 9292425
doi: 10.1002/jso.25825
Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJF, Jarnagin WR. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681–90.
pubmed: 26172135
pmcid: 4527853
doi: 10.1111/hpb.12444
Kondo S, Nimura Y, Hayakawa N, Kamiya J, Nagino M, Uesaka K. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg. 2000;87(4):418–22.
pubmed: 10759735
doi: 10.1046/j.1365-2168.2000.01384.x
Garg PK, Pandey D, Sharma J. The surgical management of gallbladder cancer. Expert Rev Gastroenterol Hepatol. 2015;9(2):155–66.
pubmed: 25155211
doi: 10.1586/17474124.2014.943188
Machairas N, Paspala A, Frountzas M, Tsilimigras DI, Moris D, Ntomi V, Tsapralis D, Schizas D. Mixed Adenoneuroendocrine Carcinoma (MANEC) of the gallbladder: a systematic review of outcomes following Surgical Management. Vivo. 2019;33(6):1721–6.
doi: 10.21873/invivo.11662
Kanetkar AV, Patkar S, Khobragade KH, Ostwal V, Ramaswamy A, Goel M. Neuroendocrine carcinoma of Gallbladder: a step beyond Palliative Therapy, experience of 25 cases. J Gastrointest Cancer. 2019;50(2):298–303.
pubmed: 29435905
doi: 10.1007/s12029-018-0070-y
Adachi T, Haraguchi M, Irie J, Yoshimoto T, Uehara R, Ito S, Tokai H, Noda K, Tada N, Hirabaru M, et al. Gallbladder small cell carcinoma: a case report and literature review. Surg Case Rep. 2016;2(1):71.
pubmed: 27457076
pmcid: 4960082
doi: 10.1186/s40792-016-0200-3
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.
pubmed: 22967994
doi: 10.1093/annonc/mds276
Oberg K, Akerström G, Rindi G, Jelic S. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v223–7.
pubmed: 20555086
doi: 10.1093/annonc/mdq192
Kim S, Yoon Y-S, Han H-S, Cho JY, Choi Y. Laparoscopic extended cholecystectomy for T3 gallbladder cancer. Surg Endosc. 2018;32(6):2984–5.
pubmed: 29218663
doi: 10.1007/s00464-017-5952-8
Elahi F, Ahmadzadeh A, Yadollahzadeh M, Hassanpour K, Babaei M. Neuroendocrine tumor of the gallbladder. Arch Iran Med. 2013;16(2):123–5.
pubmed: 23360636
Liu C, Hua X, Yang Z, Guo Y, Wu L, Cai J, Li L, Zhang Y, Fan N. Case Report: response with immunotherapy in a patient with mixed neuroendocrine non-neuroendocrine neoplasms of the Gallbladder. Front Oncol. 2021;11:770156.
pubmed: 34869003
pmcid: 8637330
doi: 10.3389/fonc.2021.770156
Chorath J, Placencio-Hickok VR, Guan M, Nissen N, Kamrava M, Klempner SJ, Nassir Y, Hendifar A, Gong J. Durable response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. Pancreas. 2020;49(2):e19–20.
pubmed: 32049953
doi: 10.1097/MPA.0000000000001480
Chu H, Shi Y, Liu J, Huang D, Zhang J, Dou C. Update in clinical management for gallbladder neuroendocrine carcinoma. Med (Baltim). 2021;100(14):e25449.
doi: 10.1097/MD.0000000000025449
Igaz P. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials]. Orv Hetil. 2014;155(48):1908–12.
pubmed: 25417137
doi: 10.1556/OH.2014.30048
Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020, 5(4).
Petersen SS, Møller S, Slott C, Krogh J, Hansen CP, Kjaer A, Holmager P, Oturai P, Garbyal RS, Langer SW et al. Responses to Medical Treatment in 192 patients with pancreatic neuroendocrine neoplasms referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020. Cancers (Basel) 2024, 16(6).
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–39.
pubmed: 30540557
doi: 10.1530/ERC-18-0424
Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, Hicks RJ. Peptide receptor radionuclide therapy (PRRT) in European neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45(2):262–77.
pubmed: 28894897
doi: 10.1007/s00259-017-3821-2
Zhang J, Kulkarni HR, Singh A, Baum RP. Ten-year survival after peptide receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 pancreatic neuroendocrine neoplasm. Clin Nucl Med. 2018;43(9):676–8.
pubmed: 30080185
doi: 10.1097/RLU.0000000000002186
Weich A, Serfling SE, Rowe SP, Solnes LB, Buck AK, Higuchi T, Werner RA. Partial response upon peptide receptor Radionuclide Therapy in a highly proliferative pancreatic neuroendocrine tumor. Clin Nucl Med. 2023;48(6):547–8.
pubmed: 36928302
doi: 10.1097/RLU.0000000000004621
Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide receptor Radionuclide Therapy in Grade 3 neuroendocrine neoplasms: Safety and Survival Analysis in 69 patients. J Nucl Med. 2019;60(3):377–85.
pubmed: 30115686
doi: 10.2967/jnumed.118.215848